Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery
Phase 1
Suspended
- Conditions
- Stage IV Cutaneous Melanoma AJCC v6 and v7Stage IIIC Cutaneous Melanoma AJCC v7
- Interventions
- First Posted Date
- 2017-12-27
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 47
- Registration Number
- NCT03384836
- Locations
- πΊπΈ
Emory University Hospital/ Winship Cancer Institute, Atlanta, Georgia, United States
πΊπΈRoswell Park Cancer Institute, Buffalo, New York, United States
πΊπΈCleveland Clinic Cancer Center, Cleveland, Ohio, United States
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Phase 1
Completed
- Conditions
- Acute Myeloid LeukemiaBlasts 30 Percent or Less of Bone Marrow Nucleated CellsChronic Myelomonocytic LeukemiaHigh Risk Myelodysplastic SyndromeMyelodysplastic SyndromeRefractory Anemia
- Interventions
- Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401Other: Laboratory Biomarker AnalysisBiological: Nivolumab
- First Posted Date
- 2017-12-02
- Last Posted Date
- 2021-10-05
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 8
- Registration Number
- NCT03358719
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Stereotactic Body Radiation Therapy Followed by Surgery in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer
Early Phase 1
Active, not recruiting
- Conditions
- Stage I Non-Small Cell Lung Cancer AJCC v7Stage IB Non-Small Cell Lung Carcinoma AJCC v7Stage II Non-Small Cell Lung Cancer AJCC v7Stage IIB Non-Small Cell Lung Carcinoma AJCC v7Stage IA Non-Small Cell Lung Carcinoma AJCC v7Stage IIA Non-Small Cell Lung Carcinoma AJCC v7Stage IIIA Non-Small Cell Lung Cancer AJCC v7
- Interventions
- Other: Laboratory Biomarker AnalysisOther: Quality-of-Life AssessmentDrug: Stereotactic Body Radiation TherapyProcedure: Thoracic Surgical Procedure
- First Posted Date
- 2017-11-21
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT03348748
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Phase 2
Active, not recruiting
- Conditions
- Acute Leukemia in RemissionAcute Myeloid LeukemiaCD40 Ligand DeficiencyChronic Lymphocytic LeukemiaGlanzmann ThrombastheniaChronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveCongenital Pure Red Cell AplasiaMyelofibrosisParoxysmal Nocturnal HemoglobinuriaSecondary Acute Myeloid Leukemia
- Interventions
- Other: Laboratory Biomarker AnalysisProcedure: Peripheral Blood Stem Cell TransplantationRadiation: Total-Body Irradiation
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 31
- Registration Number
- NCT03333486
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Intravital Microscopy in Evaluating Patients With Primary Peritoneal, Fallopian Tube, or Stage IA-IV Ovarian Cancer
Early Phase 1
Completed
- Conditions
- Fallopian Tube CarcinomaPrimary Peritoneal CarcinomaStage IIB Ovarian CancerStage IIIB Ovarian CancerStage III Ovarian CancerStage IC Ovarian CancerStage IIA Ovarian CancerStage IIC Ovarian CancerStage I Ovarian CancerStage IB Ovarian Cancer
- Interventions
- Procedure: Diagnostic MicroscopyOther: Laboratory Biomarker Analysis
- First Posted Date
- 2017-09-29
- Last Posted Date
- 2021-10-06
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 19
- Registration Number
- NCT03297489
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer
Phase 1
Active, not recruiting
- Conditions
- Advanced Adult Hepatocellular CarcinomaStage IIIB Hepatocellular CarcinomaChild-Pugh Class AStage IIIA Hepatocellular CarcinomaStage IIIC Hepatocellular CarcinomaStage IVA Hepatocellular CarcinomaStage III Hepatocellular CarcinomaStage IV Hepatocellular CarcinomaStage IVB Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2017-07-07
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 37
- Registration Number
- NCT03211416
- Locations
- πΊπΈ
Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois, United States
πΊπΈRoswell Park Cancer Institute, Buffalo, New York, United States
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Phase 1
Active, not recruiting
- Conditions
- Acute Myeloid Leukemia in RemissionAdult Acute Lymphoblastic Leukemia in Complete RemissionChronic Myelogenous Leukemia, BCR-ABL1 Positive in RemissionChronic Myelomonocytic Leukemia in RemissionGraft Versus Host DiseaseSevere Aplastic AnemiaHodgkin LymphomaMinimal Residual DiseaseMyeloproliferative NeoplasmNon-Hodgkin Lymphoma
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationOther: Laboratory Biomarker AnalysisRadiation: Total-Body Irradiation
- First Posted Date
- 2017-06-20
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 35
- Registration Number
- NCT03192397
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Photodynamic Therapy With HPPH Compared to Standard of Care Surgery in Treating Patients With Oral Cavity Cancer
Phase 2
Terminated
- Conditions
- Stage I Oral Cavity Squamous Cell CarcinomaStage II Oral Cavity Squamous Cell Carcinoma
- Interventions
- Procedure: Therapeutic Conventional SurgeryOther: Laboratory Biomarker AnalysisDrug: Photodynamic TherapyOther: Quality-of-Life Assessment
- First Posted Date
- 2017-03-24
- Last Posted Date
- 2022-06-02
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 2
- Registration Number
- NCT03090412
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
πΊπΈUniversity of Rocherster, Rochester, New York, United States
Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase 1
Active, not recruiting
- Conditions
- Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
- Interventions
- Biological: Genetically Engineered NY-ESO-1-specific T LymphocytesOther: Laboratory Biomarker Analysis
- First Posted Date
- 2017-01-11
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 9
- Registration Number
- NCT03017131
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Omission of Intact Parathyroid Hormone Testing During Surgery in Treating Patients With Primary Hyperparathyroidism
Not Applicable
Completed
- Conditions
- Parathyroid Gland AdenomaPrimary Hyperparathyroidism
- Interventions
- Other: Laboratory Biomarker AnalysisProcedure: Parathyroidectomy
- First Posted Date
- 2017-01-05
- Last Posted Date
- 2021-08-12
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 6
- Registration Number
- NCT03011736
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States